达格列净治疗初诊2型糖尿病的临床效果

Abstract
Figure/Table
References (19)
Related Citation (15)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect and safety of Dapagliflozin in the treatment of newly diagnosed type 2 diabetes mellitus.Methods A total of 70 newly diagnosed type 2 diabetes mellitus patients treated in our hospital from March 2018 to June 2019 were selected as the research subjects.The patients were divided into observation group(36 cases)and control group(34 cases)according to the randomized control principle.The patients in the observation group were treated with Dapagliflozin alone,while those in the control group were treated with Metformin alone.The blood glucose indexes(fasting blood glucose[FBG],post-prandial glucosese[PBG],glycosylated hemoglobin[HbA1c])levels,body mass index(BMI),blood pressure(systolic blood pressure[SBP],diastolic blood pressure[DBP]),lipid indicators(total cholesterol[TC],triacylglycerol[TG]),liver and kidney function indicators(alanine aminotransferase[AST],aspartate aminotransferase[ALT],creatinine[Cr])levels before and after treatment and the total incidence rate of adverse reactions were compared between the two groups of patients.Results After 12 weeks of treatment,the FBG,PBG,HbA1c,and BMI of the two groups were lower than those before treatment,and the differences were statistically significant(P＜0.05).There were no significant differences in FBG,PBG,HbA1c,and BMI between the two groups after 12 weeks of treatment(P＞0.05).After 12 weeks of treatment,the SBP,TC,and TG in the observation group were lower than those before treatment,and the differences were statistically significant(P＜0.05).The SBP in the observation group was lower than that in the control group after 12 weeks of treatment,and the difference was statistically significant(P＜0.05).There was no significant hypoglycemia or allergic reaction in both groups.The total incidence rate of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant(P＜0.05).Conclusion Dapagliflozin has a definite hypoglycemic effect in the treatment of newly diagnosed type 2 diabetes mellitus,and it can also improve a number of metabolic indicators,without obvious gastrointestinal reactions,and with high safety.

Key words： Newly diagnosed Type 2 diabetes mellitus Dapagliflozin Clinical effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TIAN Rui

Cite this article:

TIAN Rui. Clinical effect of Dapagliflozin in the treatment of newly diagnosed type 2 diabetes mellitus[J]. 中国当代医药, 2020, 27(10): 83-86.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I10/83

[1]	Xu Y，Wang LM，He J，et al.Prevalence and control of diabetes in Chinese adults[J].JAMA，2013，310（9）：948-959.
[4]	郭丽婷，葛焕琦，高志红.达格列净对使用胰岛素联合利拉鲁肽或沙格列汀治疗不理想的2 型糖尿病患者影响的研究[J].中国糖尿病杂志，2019，27（5）：343-346.
[5]	牟伦盼，蒋建家，张雅萍，等.达格列净与利格列汀对口服降糖药控制不佳的超重或肥胖2 型糖尿病患者的疗效和安全性比较[J].中华糖尿病杂志，2019，11（3）：190-195.
[2]	Ji LN，Lu JM，Guo XH，et al.Glycemic control among patients in china with type 2 diabetes mellitus receiving oral drugs or injectables[J].BMC Pubic Health，2013，21（13）：602.
[3]	Araki E，Onishi Y，Asano M，et al.Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes：results of the interim analysis of 16-week double blind treatment period[J].J Diabetes Investig，2016，7（4）：555-564.
[6]	Gupta V，Canovatchel W，Lokesh BN，et al.Sodium-glucose cotransporter-2 inhibitors：moving beyond the glycemic treatment goal[J].Indian J Endocrinol Metab，2017，21（6）：909-918.
[7]	Tosaki T，Kamiya H，Himeno T，et al.Sodium-glucose cotransporter 2 inhibitors reduce the abdominal visceral fat area and may influence the renal function in patients with type 2 diabetes[J].Intern Med，2017，56（6）：597-604.
[8]	朱凤，宋晓燕.沙格列汀治疗2 型糖尿病的疗效及其对胰岛β 细胞功能影响的研究[J].中国通糖尿病杂志，2014，22（6）：494-496.
[9]	中华医学会糖尿病学分会.中国2 型糖尿病防治指南（2013年版）[J].中国糖尿病杂志，2014，22（8）：2-42.
[10]	Goke B，Gallwitz B，Eriksson J，et al.Saxagliptin is non-inferior to glipizide in patients with type2 diabetes mellitus inadequately controlled on metformin alone：a 52-week randomized controlled trial[J].Int J Clin Prace，2010，64（12）：1619-1631.
[11]	Phillips P，Karrasch J，Scote R，et al.Acarbose imoroves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin[J].Diabetes Care，2003，26（2）：269-273.
[12]	Salvo F，More N，Arnaud M，et al.Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia：systematic reviem and meta-analysis[J].BMJ，2016，353：i2231.
[13]	母义明，李春霖，纪立农，等.二甲双胍临床应用专家共识（2018年版）[J].中国糖尿病杂志，2019，27（3）：161-173.
[14]	张波，杨文英.钠-葡萄糖共转运蛋白2 抑制剂（SGLT2i）在治疗2 型糖尿病中的有效性和安全性[J].中华内分泌代谢杂志，2016，32（2）：171-176.
[15]	Papakitsou I，Vougiouklakis G，Elisaf MS，et al.Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes[J].Clin Pharmacol，2019，11：133-143.
[16]	石佳，方振威，林阳.达格列净对2 型糖尿病患者血糖及心血管危险因素影响的Meta 分析[J].中国临床药理学杂志，2015，31（2）：116-118，134.
[17]	荆俊丽，王思明，夏晓君.达格列净安全性的研究进展[J].中国药房，2015，26（35）：5036-5038.
[18]	Sun YN，Zhou Y，Chen X，et al.The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus：meta-analysis of randomised controlled trials[J].BMJ Open，2014，4（4）：e004619.
[19]	莫小庆，黄春，赵燕妮，等.达格列净对2 型糖尿病合并冠心病患者血清hs-CRP、脂联素及胰岛素水平的影响观察[J].中国医药科学，2019，9（14）：193-196.